Breast Cancer

Double Good News For AstraZeneca's Breast Cancer Drugs
In Less Than 2 Months, Federal Health Agency Has Granted $6.4M To Study Medical Marijuana In Cancer Patients
Cannabis Cares: MariMed Commits To Breast Cancer Initiative Via Its Betty's Eddies Brand
In Less Than 2 Months, Federal Health Agency Has Granted $6.4M To Study Medical Marijuana In Cancer Patients
Cannabis Cares: MariMed Commits To Breast Cancer Initiative Via Its Betty's Eddies Brand
Breast Cancer Awareness: How Can Marijuana Companies Help? Listen To An Expert On Benzinga's Cannabis Insider
New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting

Breast Cancer Recent News

Celcuity Plans To Start Pivotal Gedatolisib Trial In Breast Cancer In 1H 2022
Why Sanofi Shares Are Trading Lower Today
Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, 
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
The 
NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting
FDA Backs Immutep's Eftilagimod Registrational Trial In Metastatic Breast Cancer
Immutep Limited (NASDAQ: IMMP) has 
Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint
Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer.
AstraZeneca's Stock Gain After Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting
AstraZeneca plc (NASDAQ: AZN) said that 
Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has 
Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings
Merus NV (NASDAQ: MRUS) has 
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
Infinity Pharmaceuticals Inc (NASDAQ: INFI) 
Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients
Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer
Context Therapeutics Inc (NASDAQ: CNTX) posted 
Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial
Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented 
Seagen Tukysa Maintains Survival Benefit, Delays Cancer Progression In The Brain In Breast Cancer Patients
Seagen Inc (NASDAQ: SGEN) has 
Novartis' New Kisqali Data Shows Consistent Overall Survival Benefit Across Metastatic Breast Cancer Settings
Radius Health Reveals Detailed Elacestrant Data From Late-Stage Breast Cancer Trial
The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have 
After Denying Data Leak, Olema Shares First Data For Lead Program In Breast Cancer Patients
Olema Pharmaceuticals Inc (NASDAQ: OLMA) had been preparing to present the first clinical data from its lead program in development for metastatic breast cancer at a 
AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting
The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: <
Merck's Keytruda Conditionally Approved In Canada For Triple-Negative Breast Cancer
Gilead's Trodelvy Approved In Europe For Aggressive Form Of Breast Cancer
The European Commission has approved Gilead Sciences Inc's (NASDAQ:
Athenex To Present Subgroup Analysis Of Oral Paclitaxel-Encequidar Combo Data From Breast Cancer Trial
Athenex Inc's (NASDAQ: ATNX) abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for metastatic breast cancer has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium.
Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients
Jaguar Health Inc (NASDAQ: JAGX) 
Immutep's Lead Candidate Data In Breast Cancer Trial Fails To Lift The Stock